Heron Therapeutics, Inc. (NASDAQ:HRTX) has been assigned a $31.00 price objective by research analysts at Cantor Fitzgerald in a report released on Friday. The firm presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 100.00% from the company’s current price.

A number of other equities analysts have also recently issued reports on HRTX. ValuEngine upgraded Heron Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Zacks Investment Research upgraded Heron Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a report on Wednesday, July 12th. Jefferies Group LLC restated a “buy” rating and set a $26.00 target price on shares of Heron Therapeutics in a report on Friday, July 14th. Aegis restated a “buy” rating and set a $33.00 target price on shares of Heron Therapeutics in a report on Tuesday, July 18th. Finally, Cowen and Company set a $40.00 target price on Heron Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $28.50.

Heron Therapeutics (NASDAQ HRTX) traded up 3.68% during mid-day trading on Friday, reaching $15.50. The company’s stock had a trading volume of 915,623 shares. Heron Therapeutics has a 12 month low of $12.21 and a 12 month high of $20.85. The stock’s 50 day moving average is $15.82 and its 200 day moving average is $15.19. The company’s market cap is $839.14 million.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.10. The company had revenue of $8.51 million for the quarter, compared to the consensus estimate of $4.53 million. Equities research analysts predict that Heron Therapeutics will post ($3.51) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/10/20/heron-therapeutics-inc-hrtx-pt-set-at-31-00-by-cantor-fitzgerald.html.

Several large investors have recently added to or reduced their stakes in HRTX. Janus Henderson Group PLC bought a new position in shares of Heron Therapeutics during the 2nd quarter valued at about $78,134,000. FMR LLC lifted its holdings in shares of Heron Therapeutics by 36.7% during the 1st quarter. FMR LLC now owns 8,030,880 shares of the biotechnology company’s stock valued at $120,464,000 after purchasing an additional 2,158,041 shares in the last quarter. Janus Capital Management LLC lifted its holdings in shares of Heron Therapeutics by 20.2% during the 1st quarter. Janus Capital Management LLC now owns 5,501,755 shares of the biotechnology company’s stock valued at $82,524,000 after purchasing an additional 925,948 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Heron Therapeutics by 40.2% during the 1st quarter. Vanguard Group Inc. now owns 1,875,103 shares of the biotechnology company’s stock valued at $28,127,000 after purchasing an additional 537,563 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of Heron Therapeutics by 30.7% during the 1st quarter. State Street Corp now owns 1,787,678 shares of the biotechnology company’s stock valued at $26,822,000 after purchasing an additional 420,113 shares in the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.